title: Botulinum toxin B is not an effective treatment of refractory overactive bladder.
abstract: OBJECTIVE
  To determine the efficacy and safety of botulinum toxin-B (BTX-B) in two groups of patients with urodynamically proven idiopathic detrusor overactivity (IDO) or neurogenic DO (NDO) refractory to conservative treatment.
  
  
  METHODS
  This was a nonrandomized, prospective study. We diluted 5000 U of BTX-B in 20 mL of normal saline and injected it at 20 sites around the bladder, avoiding the trigone. The data collected at recruitment and 10 and 26 weeks postoperatively included number of incontinent episodes, frequency, and nocturia, King's Health Questionnaire score, and the urodynamic parameters of volume at the first overactive contraction and maximal cystometric capacity.
  
  
  RESULTS
  A total of 25 patients were recruited, 20 with IDO and 5 with NDO. Only 7 patients, all with IDO, reported symptomatic improvement at the 10-week assessment. The symptoms had returned in these 7 patients at a median of 136 days (range 106 to 151) after injection. Of the remaining 20 patients, 16 (13 with IDO and 3 with NDO) thought an initial improvement had occurred but it had worn off or was wearing off by the first assessment. Two patients (both with NDO) reported no improvement.
  
  
  CONCLUSIONS
  BTX-B had a limited duration of action, with most of its symptomatically beneficial effects wearing off by 10 weeks in most of our patients. The short duration of action for BTX-B suggests it is unlikely to gain widespread use in the treatment of DO.
authors.affiliation: Joint Urogynaecology Unit, Swansea National Health Service Trust, Swansea, Wales, United Kingdom. grahamrhirst@yahoo.co.uk
authors.forename: G R
authors.initials: GR
authors.lastname: Hirst
authors.forename: A J
authors.initials: AJ
authors.lastname: Watkins
authors.forename: K
authors.initials: K
authors.lastname: Guerrero
authors.forename: K
authors.initials: K
authors.lastname: Wareham
authors.forename: S J
authors.initials: SJ
authors.lastname: Emery
authors.forename: D R
authors.initials: DR
authors.lastname: Jones
authors.forename: M G
authors.initials: MG
authors.lastname: Lucas
mesh_terms: D000328:Adult; D000368:Aged; D001905:Botulinum Toxins / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D017211:Treatment Failure; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A